Literature DB >> 15198874

S-100B protein as a serum marker of secondary neurological complications in neurocritical care patients.

Andreas Raabe1, Olaf Kopetsch, Alina Woszczyk, Josef Lang, Rüdiger Gerlach, Michael Zimmermann, Volker Seifert.   

Abstract

There is growing evidence that S-100B protein measured by a simple blood test can be used as a novel biochemical marker of brain cell damage. The objective of our study was to investigate the potential of S-100B measurements to diagnose an acute neurological complication in the analgo-sedated and intubated intensive care patient and the impact on patient management. Serum S-100B levels were serially investigated in 246 neurocritical care patients. Venous blood samples for S-100B determination were obtained as soon as possible after admission and every 24 hours thereafter, for the duration of the stay at the neurocritical care unit. Blood samples were taken every morning as part of the routine laboratory investigation for analysis of S-100B using the immunoluminometric assay (AB Sangtec Medical, Bromma, Sweden) and a fully automated LIAISON system (Byk-Sangtec-Diagnostica, Dietzenbach, Germany) with a short time to result. The primary endpoint of our study was the occurrence of a severe neurological complication. Patients were admitted to the neurosurgical intensive care unit after routine major intracranial surgery in 116 cases (47%) and after a neurological or neurosurgical emergency in 130 cases (53%). Of the latter group, 79 patients (32%) underwent emergency surgery for evacuation or decompression of a space-occupying lesion before ICU admission. A severe neurological complication was defined as a new infarction, new hemorrhage or a newly developed progressive disease despite maximum therapy with a radiologically confirmed increase of mass lesion and midline shift. In 33 patients (13%) a complication with neurological deterioration occurred. All patients showed pathologically increased serum S-100B values (mean 2.00 microg/l, standard deviation 2.61 microg/l, range 0.31-9.66 microg/l). Twenty-eight of these patients (85%) showed S-100B increases >0.5 microg/l. In five cases (16%), the increase in S-100B was the first sign of neurological complication and prompted emergency computed tomography scanning. In another two cases, increasing S-100B values changed management decision towards a surgical intervention. The major finding of our study was the influence of serial S-100B measurement on actual management of the patient in 21% of cases with neurological complications. Copyright 2004 W.S. Maney and Son Ltd

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198874     DOI: 10.1179/016164104225015958

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  20 in total

1.  Effect of magnesium sulfate therapy on patients with aneurysmal subarachnoid hemorrhage using serum S100B protein as a prognostic marker.

Authors:  Tamer Hassan; Mahmoud Nassar; Sherif Mohammed Elhadi; Wafa Kamel Radi
Journal:  Neurosurg Rev       Date:  2011-12-15       Impact factor: 3.042

Review 2.  Current state of high-fidelity multimodal monitoring in traumatic brain injury.

Authors:  Caroline Lindblad; Rahul Raj; Frederick A Zeiler; Eric P Thelin
Journal:  Acta Neurochir (Wien)       Date:  2022-10-19       Impact factor: 2.816

3.  Assessing bicycle-related trauma using the biomarker S100B reveals a correlation with total injury severity.

Authors:  E P Thelin; E Zibung; L Riddez; C Nordenvall
Journal:  Eur J Trauma Emerg Surg       Date:  2015-10-21       Impact factor: 3.693

4.  Serum S100B protein could help to detect cerebral complications associated with extracorporeal membrane oxygenation (ECMO).

Authors:  Duc Nam Nguyen; Luc Huyghens; Francis Wellens; Johan Schiettecatte; Johan Smitz; Jean-Louis Vincent
Journal:  Neurocrit Care       Date:  2014-06       Impact factor: 3.210

5.  Secondary peaks of S100B in serum relate to subsequent radiological pathology in traumatic brain injury.

Authors:  Eric P Thelin; David W Nelson; Bo-Michael Bellander
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

6.  Is peripheral immunity regulated by blood-brain barrier permeability changes?

Authors:  Erin Bargerstock; Vikram Puvenna; Philip Iffland; Tatiana Falcone; Mohammad Hossain; Stephen Vetter; Shumei Man; Leah Dickstein; Nicola Marchi; Chaitali Ghosh; Juliana Carvalho-Tavares; Damir Janigro
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

7.  Serum neurofilament light protein predicts clinical outcome in traumatic brain injury.

Authors:  Pashtun Shahim; Magnus Gren; Victor Liman; Ulf Andreasson; Niklas Norgren; Yelverton Tegner; Niklas Mattsson; Niels Andreasen; Martin Öst; Henrik Zetterberg; Bengt Nellgård; Kaj Blennow
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

8.  Lesion Size Is Exacerbated in Hypoxic Rats Whereas Hypoxia-Inducible Factor-1 Alpha and Vascular Endothelial Growth Factor Increase in Injured Normoxic Rats: A Prospective Cohort Study of Secondary Hypoxia in Focal Traumatic Brain Injury.

Authors:  Eric Peter Thelin; Arvid Frostell; Jan Mulder; Nicholas Mitsios; Peter Damberg; Sahar Nikkhou Aski; Mårten Risling; Mikael Svensson; Maria Cristina Morganti-Kossmann; Bo-Michael Bellander
Journal:  Front Neurol       Date:  2016-03-07       Impact factor: 4.003

9.  Case Report: Extreme Levels of Serum S-100B in a Patient with Chronic Subdural Hematoma.

Authors:  Malin Elisabet Persson; Eric Peter Thelin; Bo-Michael Bellander
Journal:  Front Neurol       Date:  2012-12-05       Impact factor: 4.003

10.  Clinical significance of serum S100B levels in neurointensive care.

Authors:  Johan Undén; Ramona Astrand; Knut Waterloo; Tor Ingebrigtsen; Johan Bellner; Peter Reinstrup; Gunnar Andsberg; Bertil Romner
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.